Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

Aridis discontinuing antibacterial mAb
Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary endpoint of superiority to antibiotics alone in a Phase II trial to treat ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa. Aridis will

Read the full 406 word article

User Sign In